Association between Serotonin Transporter-Linked Polymorphic Region and Escitalopram Antidepressant Treatment Response in Korean Patients with Major Depressive Disorder
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Won, Eun-Soo | - |
dc.contributor.author | Chang, Hun-Soo | - |
dc.contributor.author | Lee, Hwa-Young | - |
dc.contributor.author | Ham, Byung-Joo | - |
dc.contributor.author | Lee, Min-Soo | - |
dc.date.accessioned | 2021-09-06T23:43:29Z | - |
dc.date.available | 2021-09-06T23:43:29Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0302-282X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/109272 | - |
dc.description.abstract | Objective: Various studies have shown that short (s)/long (I) polymorphisms of the serotonin transporter-linked polymorphic region (5-HTTLPR) might predict treatment outcome to selective serotonin reuptake inhibitors. The purpose of this study was to evaluate the association between 5-HTTLPR and clinical response to escitalopram treatment in Korean subjects with major depressive disorder. Methods: One hundred and fifteen Korean patients diagnosed with major depressive disorder were evaluated during 8 weeks of escitalopram treatment at a dose of 5-20 mg/day. Patients were genotyped for 5-HTTLPR using polymerase chain reaction. Clinical symptoms were evaluated by the 21-item Hamilton Depression Rating (HAMD-21) scale during the 8 weeks of treatment. Results: Therapeutic response to antidepressant escitalopram was better in s allele carriers (ss, sl) than in I allele homozygotes (II) at 8 weeks of treatment (OR = 6.24, p = 0.026). The proportion of s allele carriers in responders was higher than that in non-responders (96.6 vs. 85.7%). The percentile decline in HAMD-21 in s allele carriers (59.86 +/- 3.23%) was larger than that in HAMD-21 in I allele homozygotes (43.13 +/- 11.49%; p = 0.029). However, 5-HTTLPR genotypes were not significantly associated with remission (p > 0.05). Conclusions: Our results show that treatment response to escitalopram at 8 weeks was moderated by 5-HTTLPR, with better response rates for s allele carriers than for I allele homozygotes. Although the role of 5-HTTLPR as a definite predictor of selective serotonin reuptake inhibitor treatment response cannot be confirmed from current results, they do suggest a trend for better response in s allele carriers. Copyright (c) 2012 S. Karger AG, Basel | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KARGER | - |
dc.subject | OBSESSIVE-COMPULSIVE DISORDER | - |
dc.subject | LATE-LIFE DEPRESSION | - |
dc.subject | GENE POLYMORPHISMS | - |
dc.subject | REUPTAKE INHIBITORS | - |
dc.subject | PROMOTER POLYMORPHISM | - |
dc.subject | ALLELIC VARIATION | - |
dc.subject | 5-HTTLPR | - |
dc.subject | SLC6A4 | - |
dc.subject | EFFICACY | - |
dc.subject | GENOTYPE | - |
dc.title | Association between Serotonin Transporter-Linked Polymorphic Region and Escitalopram Antidepressant Treatment Response in Korean Patients with Major Depressive Disorder | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Chang, Hun-Soo | - |
dc.contributor.affiliatedAuthor | Lee, Min-Soo | - |
dc.identifier.doi | 10.1159/000341876 | - |
dc.identifier.scopusid | 2-s2.0-84867665768 | - |
dc.identifier.wosid | 000311601100003 | - |
dc.identifier.bibliographicCitation | NEUROPSYCHOBIOLOGY, v.66, no.4, pp.221 - 229 | - |
dc.relation.isPartOf | NEUROPSYCHOBIOLOGY | - |
dc.citation.title | NEUROPSYCHOBIOLOGY | - |
dc.citation.volume | 66 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 221 | - |
dc.citation.endPage | 229 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalResearchArea | Psychology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Psychology | - |
dc.subject.keywordPlus | OBSESSIVE-COMPULSIVE DISORDER | - |
dc.subject.keywordPlus | LATE-LIFE DEPRESSION | - |
dc.subject.keywordPlus | GENE POLYMORPHISMS | - |
dc.subject.keywordPlus | REUPTAKE INHIBITORS | - |
dc.subject.keywordPlus | PROMOTER POLYMORPHISM | - |
dc.subject.keywordPlus | ALLELIC VARIATION | - |
dc.subject.keywordPlus | 5-HTTLPR | - |
dc.subject.keywordPlus | SLC6A4 | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | GENOTYPE | - |
dc.subject.keywordAuthor | Major depressive disorder | - |
dc.subject.keywordAuthor | Serotonin transporter-linked polymorphic region | - |
dc.subject.keywordAuthor | Escitalopram treatment response | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.